The US Food and Drug Administration approved this first-in-class medication for the management of type 2 diabetes (T2D) in 2022 [2], for the reduction of excess weight in adults with obesity or overweight in 2023 [3], and for moderate-to-severe obstructive sleep apnea (OSA) in people with obesity in 2024 [4]
These costs, in addition to step therapy requirements from many payers, further limit access, as Banas notes
When stockists stop purchasing, pharmaceutical companiesincluding major players like Torrent Pharmaceuticals, Sun Pharma, and Dr Reddy's, who launched generic versions after the patent expirysee an immediate pause in secondary sales growth
Others tolerate higher doses with favorable outcomes
The team is very knowledgeable